The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover...
The University of Texas MD Anderson Cancer Center and Rice University today announced the creation of the Cancer Bioengineering Collaborative...
ABSTRACTS: LB3439, LB3442, S131, S132, S136, S164, S222
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases...
The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Under the agreement, Sibylla and MD Anderson will jointly conduct discovery and development work from target identification...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the appointment of its newest members,...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel...
The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the appointment...
The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals,...
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop...